LOK Corporation Announces its Latest Representation: the Alteco LPS Adsorber for Extracorporeal Endotoxin Elimination
Publishing date: 4 November 2020
The Alteco LPS Adsorber by Alteco Medical AB (ALTE:SS) is used in hemoperfusion to remove endotoxin (LPS) from the bloodstream for the treatment of endotoxemia, sepsis or septic shock caused gram-negative bacteria. LOK Corporation is proud to now represent Alteco Medical internationally.
Sepsis is the body’s overwhelming, dysregulated response to an infection, which may lead to tissue damage, acute failure of multiple organs including lungs, kidneys and liver, and even death. With nearly 49 million cases worldwide and 11 million deaths globally per year – or 1 in 5 – it is now thought that sepsis kills more people than cancer.1
Alteco LPS Adsorber – part of the ICU toolkit in COVID-19
Some COVID-19 patients in ICU suffer from cytokine storms, a severe immune response that can have life-threatening consequences. Endotoxin is among the most potent bacterial inducers of cytokines2 and by removing endotoxin from the bloodstream, it may be possible to avoid further damage to vital organs and tissues. The Alteco LPS Adsorber offers ICU teams an innovative and effective tool to complement best practice medical treatment for patients suffering from heightened immune response from endotoxin-induced cytokine storms.
Severely ill COVID-19 patients are also at high risk of sepsis due to secondary gram-negative bacterial infections. Nearly 60% of COVID-19 patients in the ICU have secondary bacterial infections – most commonly respiratory infections from gram-negative bacteria. Also, using mechanical and hemodynamic support heightens the immune response of the patient. Being on ECMO- and/or a CRRT machine, the patient may have an inflammatory response to extracorporeal circulation (complement activation) resulting in increased endotoxin levels. The Alteco LPS Adsorber may therefore be of use in COVID-19 patients suspected to have gram-negative bacterial infection and/or signs of inflammatory response.3,4,5,6
The Alteco LPS Adsorber, a class IIa medical device, is very safe to use with no contraindications and no side effects, adverse events or allergic reactions reported.
We look forward to expanding Alteco Medical’s reach to make sure that patients in the ICU can benefit from the most advanced medical treatments available: “We are all facing the COVID-19 crisis together. When we were presented with the opportunity of representing the Alteco LPS Adsorber, our product review committee was very enthusiastic – Alteco LPS Adsorber does not only treat symptoms of gram-negative infections, but can counteract the sepsis process altogether”, commented Daniel Cloutier, CEO of LOK Corporation.
Alteco Medical will seek LOK Corporation’s expertise at expanding distribution channels to leverage the current increased need for the Alteco LPS Adsorber. “We are very excited about the collaboration with LOK Corporation. With a vast network of competent distributors, we aim to offer our product to many new markets in a rapid pace. The acceptance for extracorporeal treatments is increasing and with the current global situation we believe that this is an optimal time for expanding our sales channels focusing on Intensive Care Units”, added Fredrik Jonsson, CEO of Alteco Medical.
About LOK Corporation
LOK Corporation is a manufacturing agent that helps companies develop and manage their international distribution network. Over the years, LOK has built a reputation representing major players and start-ups from the medical industry. LOK also offers training tools for the sales force and several other services to support sales & marketing.
About Alteco Medical
Alteco Medical is in the business of extracorporeal adsorption of human toxins in acute and planned hospital treatments. Our mission is to safely stabilize patients in toxic immune response situations. Alteco Medical provides a solution for hospitals across the world to remove endotoxin (lipopolysaccharides, LPS) in the patient’s bloodstream to counteract the threat of endotoxemia during their hospital stay. Our product, the Alteco LPS Adsorber, contains a specific, tailor-made synthetic peptide that binds to Lipid A, the toxic part of LPS.
- The Lancet, Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study
- Exotoxins and endotoxins: Inducers of inflammatory cytokines
- European Sepsis Alliance: Update: Can COVID-19 Cause Sepsis? Explaining the Relationship Between the Coronavirus Disease and Sepsis
- Risks and features of secondary infections in severe and critical ill COVID-19 patients
- The Lancet: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- PubMed: Elevated levels of endotoxin, oxygen-derived free radicals, and cytokines during extracorporeal membrane oxygenation